NASDAQ:TVRD Tvardi Therapeutics 5/8/2026 Earnings Report $3.38 -0.11 (-3.15%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$3.39 +0.01 (+0.30%) As of 05/29/2026 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Tvardi Therapeutics EPS ResultsActual EPS-$0.73Consensus EPS -$0.65Beat/MissMissed by -$0.08One Year Ago EPSN/ATvardi Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATvardi Therapeutics Announcement DetailsQuarterDate5/8/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Tvardi Therapeutics Earnings HeadlinesTvardi Therapeutics to Participate in Upcoming Investor EventsMay 21, 2026 | globenewswire.comOppenheimer Sticks to Its Buy Rating for Tvardi Therapeutics (TVRD)May 13, 2026 | theglobeandmail.comGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.May 31 at 1:00 AM | Behind the Markets (Ad)Tvardi Therapeutics (TVRD) Receives a Buy from BTIGMay 11, 2026 | theglobeandmail.comTvardi Therapeutics Announces First Quarter 2026 Results and Provides Business UpdateMay 8, 2026 | globenewswire.comBarclays downgrades Tvardi Therapeutics (TVRD)April 21, 2026 | msn.comSee More Tvardi Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tvardi Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tvardi Therapeutics and other key companies, straight to your email. Email Address About Tvardi TherapeuticsCara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.View Tvardi Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 05/25 - 05/29Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%Costco’s Strong Quarter Still Leaves Investors With a Valuation ProblemMongoDB's AI Advantage Is Starting to Show Up in ResultsShares Fall, Targets Rise—Markets and Analysts Diverge on SynopsysDollar Tree Keeps Winning After Family Dollar DivorceSalesforce Stock Finds Support as AI Momentum Builds Upcoming Earnings Hewlett Packard Enterprise (6/1/2026)Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
